Synthetic ghrelin mimetic — binds GHS-R1a receptor on pituitary somatotrophs. Stimulates GH pulse without requiring CRH co-administration. Less gastric motility effect than GHRP-6. Moderate cortisol and prolactin co-stimulation. Synergistic with CJC-1295 or Mod-GRF(1-29).
Studies have administered: 100–300mcg per injection in research contexts; often combined with GHRH analogue
Robust GH pulsatile release demonstrated across multiple human studies. GH secretagogue clinical pharmacology well-characterized. Body composition improvements in GH-deficient subjects. IGF-1 elevation dose-dependent.
Water retention; mild appetite increase (less than GHRP-6); transient cortisol and prolactin elevation; injection site reactions
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on GHRP-2 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat